 [1m([0morchestrator-bleeding-ALENDRONATE SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ALENDRONATE SODIUM increase or decrease the risk of bleeding?[0m
 [1m([0morchestrator-bleeding-ALENDRONATE SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-ALENDRONATE SODIUM[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-bleeding-ALENDRONATE SODIUM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ALENDRONATE SODIUM increase the risk of bleeding?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-bleeding-ALENDRONATE SODIUM[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ALENDRONATE SODIUM increase the risk of bleeding?[0m
 [1m([0morchestrator-bleeding-ALENDRONATE SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-ALENDRONATE SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-bleeding-ALENDRONATE SODIUM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ALENDRONATE SODIUM increase the risk of bleeding?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ALENDRONATE SODIUM increase the risk of bleeding?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"ALENDRONATE SODIUM"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: ALENDRONATE SODIUM: warnings_and_cautions: [0m[1;31m5[0m[31m WARNINGS AND PRECAUTIONS Upper Gastrointestinal Adverse Reactions can occur. Instruct patients to follow dosing instructions. Discontinue if new [0m
[31mor worsening symptoms occur. [0m[1;31m([0m[31m [0m[1;31m5.1[0m[31m [0m[1;31m)[0m[31m Hypocalcemia can worsen and must be corrected prior to use. [0m[1;31m([0m[31m [0m[1;31m5.2[0m[31m [0m[1;31m)[0m[31m Severe Bone, Joint, Muscle Pain may occur. Discontinue use if severe symptoms develop. [0m[1;31m([0m[31m [0m[1;31m5.3[0m[31m [0m[1;31m)[0m[31m [0m
[31mOsteonecrosis of the Jaw has been reported. [0m[1;31m([0m[31m [0m[1;31m5.4[0m[31m [0m[1;31m)[0m[31m Atypical Femur Fractures have been reported. Patients with new thigh or groin pain should be evaluated to rule out a femoral fracture. [0m[1;31m([0m[31m [0m[1;31m5.5[0m[31m [0m[1;31m)[0m[31m [0m
[31mSodium Content: Each tablet contains [0m[1;31m603[0m[31m mg sodium, equivalent to [0m[1;31m1532[0m[31m mg NaCl. Use caution in patients on sodium restriction. [0m[1;31m([0m[31m [0m[1;31m5.7[0m[31m [0m[1;31m)[0m[31m [0m[1;31m5[0m[31m. ALENDRONATE SODIUM: warnings_and_cautions: [0m[1;31m1[0m[31m Upper [0m
[31mGastrointestinal Adverse Reactions BINOSTO, like other bisphosphonates administered orally, may cause local irritation of the upper gastrointestinal mucosa. Because of these possible irritant effects [0m
[31mand a potential for worsening of the underlying disease, caution should be used when BINOSTO is given to patients with active upper gastrointestinal problems [0m[1;31m([0m[31msuch as known Barrett's esophagus, [0m
[31mdysphagia, other esophageal diseases, gastritis, duodenitis, or ulcers[0m[1;31m)[0m[31m. Esophageal adverse experiences, such as esophagitis, esophageal ulcers and esophageal erosions, occasionally with bleeding and [0m
[31mrarely followed by esophageal stricture or perforation, have been reported in patients receiving treatment with oral bisphosphonates including alendronate sodium. In some cases these have been severe [0m
[31mand required hospitalization. ALENDRONATE SODIUM: warnings_and_cautions: Physicians should therefore be alert to any signs or symptoms signaling a possible esophageal reaction and patients should be [0m
[31minstructed to discontinue BINOSTO and seek medical attention if they develop dysphagia, odynophagia, retrosternal pain or new or worsening heartburn. The risk of severe esophageal adverse experiences [0m
[31mappears to be greater in patients who lie down after taking oral bisphosphonates including alendronate sodium, and/or who continue to take oral bisphosphonates including alendronate sodium after [0m
[31mdeveloping symptoms suggestive of esophageal irritation. Therefore, it is very important that the full dosing instructions are provided to, and understood by, the patient [0m[31m . In patients who cannot [0m
[31mcomply with dosing instructions due to mental disability, therapy with BINOSTO should be used under appropriate supervision. ALENDRONATE SODIUM: warnings_and_cautions: There have been post-marketing [0m
[31mreports of gastric and duodenal ulcers with oral bisphosphonate use, some severe and with complications, although no increased risk was observed in controlled clinical trials [0m[31m . [0m[1;31m5.2[0m[31m Mineral Metabolism[0m
[31mHypocalcemia must be corrected before initiating therapy with BINOSTO [0m[31m. Other disorders affecting mineral metabolism [0m[1;31m([0m[31msuch as vitamin D deficiency[0m[1;31m)[0m[31m should also be effectively treated. In patients with[0m
[31mthese conditions, serum calcium and symptoms of hypocalcemia should be monitored during therapy with BINOSTO. Presumably due to the effects of BINOSTO on increasing bone mineral, small, asymptomatic [0m
[31mdecreases in serum calcium and phosphate may occur. Patients should receive adequate calcium and vitamin D intake. [0m[1;31m5[0m[31m. ALENDRONATE SODIUM: warnings_and_cautions: [0m[1;31m3[0m[31m Musculoskeletal Pain In [0m
[31mpost-marketing experience, severe and occasionally incapacitating bone, joint, and/or muscle pain has been reported in patients taking bisphosphonates that are approved for the treatment of [0m
[31mosteoporosis [0m[31m . This category of drugs includes BINOSTO. Most of the patients were postmenopausal women. The time to onset of symptoms varied from one day to several months after starting the drug. [0m
[31mDiscontinue use if severe symptoms develop. Most patients had relief of symptoms after stopping. A subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate. In [0m
[31mplacebo-controlled clinical studies of alendronate sodium, the percentages of patients with these symptoms were similar in the alendronate sodium and placebo groups. [0m[1;31m5[0m[31m. ALENDRONATE SODIUM: [0m
[31mwarnings_and_cautions: [0m[1;31m4[0m[31m Osteonecrosis of the Jaw Osteonecrosis of the jaw [0m[1;31m([0m[31mONJ[0m[1;31m)[0m[31m, which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed [0m
[31mhealing, and has been reported in patients taking bisphosphonates, including alendronate sodium. Known risk factors for osteonecrosis of the jaw include invasive dental procedures [0m[1;31m([0m[31me.g., tooth [0m
[31mextraction, dental implants, boney surgery[0m[1;31m)[0m[31m, diagnosis of cancer, concomitant therapies [0m[1;31m([0m[31me.g., chemotherapy, corticosteroids, angiogenesis inhibitors[0m[1;31m)[0m[31m, poor oral hygiene, and co-morbid disorders [0m
[1;31m([0m[31me.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures[0m[1;31m)[0m[31m. The risk of ONJ may increase with duration of exposure to bisphosphonates. For [0m
[31mpatients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ. ALENDRONATE SODIUM: warnings_and_cautions: Clinical judgment of the treating [0m
[31mphysician and/or oral surgeon should guide the management plan of each patient based on individual benefit/risk assessment. Patients who develop osteonecrosis of the jaw while on bisphosphonate [0m
[31mtherapy should receive care by an oral surgeon. In these patients, extensive dental surgery to treat ONJ may exacerbate the condition. Discontinuation of bisphosphonate therapy should be considered [0m
[31mbased on individual benefit/risk assessment. [0m[1;31m5.5[0m[31m Atypical Subtrochanteric and Diaphyseal Femoral Fractures Atypical, low-energy, or low trauma fractures of the femoral shaft have been reported in [0m
[31mbisphosphonate-treated patients. These fractures can occur anywhere in the femoral shaft from just below the lesser trochanter to above the supracondylar flare and are transverse or short oblique in [0m
[31morientation without evidence of comminution. ALENDRONATE SODIUM: warnings_and_cautions: Causality has not been established as these fractures also occur in osteoporotic patients who have not been [0m
[31mtreated with bisphosphonates. Atypical femur fractures most commonly occur with minimal or no trauma to the affected area. They may be bilateral and many patients report prodromal pain in the affected[0m
[31marea, usually presenting as dull, aching thigh pain, weeks to months before a complete fracture occurs. A number of reports note that patients were also receiving treatment with glucocorticoids [0m[1;31m([0m[31me.g.,[0m
[31mprednisone[0m[1;31m)[0m[31m at the time of fracture. Any patient with a history of bisphosphonate exposure who presents with thigh or groin pain should be suspected of having an atypical fracture and should be [0m
[31mevaluated to rule out an incomplete femur fracture. Patients presenting with an atypical fracture should also be assessed for symptoms and signs of fracture in the contralateral limb.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE SODIUM label[0m


[31mCONTENT: ALENDRONATE SODIUM: indications_and_usage: [0m[1;31m1[0m[31m INDICATIONS AND USAGE BINOSTO is a bisphosphonate indicated for: Treatment of osteoporosis in postmenopausal women [0m[1;31m([0m[31m [0m[1;31m1.1[0m[31m [0m[1;31m)[0m[31m Treatment to increase [0m
[31mbone mass in men with osteoporosis [0m[1;31m([0m[31m [0m[1;31m1.2[0m[31m [0m[1;31m)[0m[31m Limitation of use: Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after [0m[1;31m3[0m[31m to [0m[1;31m5[0m[31m years [0m
[31mof use [0m[1;31m([0m[31m [0m[1;31m1.3[0m[31m [0m[1;31m)[0m[31m [0m[1;31m1.1[0m[31m Treatment of Osteoporosis in Postmenopausal Women BINOSTO effervescent tablet [0m[1;31m70[0m[31m mg is indicated for the treatment of osteoporosis in postmenopausal women. For the treatment of [0m
[31mosteoporosis, alendronate sodium increases bone mass and reduces the incidence of fractures, including those of the hip and spine [0m[1;31m([0m[31mvertebral compression fractures[0m[1;31m)[0m[31m. [0m[1;31m[[0m[31mSee Clinical Studies [0m[1;31m([0m[1;31m14.1[0m[1;31m)[0m[31m .[0m[1;31m][0m[31m [0m[1;31m1[0m[31m. [0m
[31mALENDRONATE SODIUM: indications_and_usage: [0m[1;31m2[0m[31m Treatment to Increase Bone Mass in Men With Osteoporosis BINOSTO is indicated for treatment to increase bone mass in men with osteoporosis [0m[31m . [0m[1;31m1.3[0m[31m Important[0m
[31mLimitations of Use The optimal duration of use has not been determined. The safety and effectiveness of BINOSTO for the treatment of osteoporosis are based on clinical data of four years duration. All[0m
[31mpatients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. Patients at low-risk for fracture should be considered for drug discontinuation after [0m[1;31m3[0m[31m [0m
[31mto [0m[1;31m5[0m[31m years of use. Patients who discontinue therapy should have their risk for fracture re-evaluated periodically.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE SODIUM label[0m


[31mCONTENT: ALENDRONATE SODIUM: pharmacodynamics: [0m[1;31m12.2[0m[31m Pharmacodynamics Alendronate is a bisphosphonate that binds to bone hydroxyapatite and specifically inhibits the activity of osteoclasts, the [0m
[31mbone-resorbing cells. Alendronate reduces bone resorption with no direct effect on bone formation, although the latter process is ultimately reduced because bone resorption and formation are coupled [0m
[31mduring bone turnover. Osteoporosis in Postmenopausal Women Osteoporosis is characterized by low bone mass that leads to an increased risk of fracture. The diagnosis can be confirmed by the finding of [0m
[31mlow bone mass, evidence of fracture on x-ray, a history of osteoporotic fracture, or height loss or kyphosis, indicative of vertebral [0m[1;31m([0m[31mspinal[0m[1;31m)[0m[31m fracture. Osteoporosis occurs in both males and females [0m
[31mbut is most common among women following the menopause, when bone turnover increases and the rate of bone resorption exceeds that of bone formation. ALENDRONATE SODIUM: pharmacodynamics: These changes[0m
[31mresult in progressive bone loss and lead to osteoporosis in a significant proportion of women over age [0m[1;31m50[0m[31m. Fractures, usually of the spine, hip, and wrist, are the common consequences. From age [0m[1;31m50[0m[31m to [0m
[31mage [0m[1;31m90[0m[31m, the risk of hip fracture in white women increases [0m[1;31m50[0m[31m-fold and the risk of vertebral fracture [0m[1;31m15[0m[31m- to [0m[1;31m30[0m[31m-fold. It is estimated that approximately [0m[1;31m40[0m[31m% of [0m[1;31m50[0m[31m-year-old women will sustain one or [0m
[31mmore osteoporosis-related fractures of the spine, hip, or wrist during their remaining lifetimes. Hip fractures, in particular, are associated with substantial morbidity, disability, and mortality. [0m
[31mALENDRONATE SODIUM: pharmacodynamics: Daily oral doses of alendronate sodium [0m[1;31m([0m[1;31m5[0m[31m, [0m[1;31m20[0m[31m, and [0m[1;31m40[0m[31m mg for six weeks[0m[1;31m)[0m[31m in postmenopausal women produced biochemical changes indicative of dose-dependent [0m
[31minhibition of bone resorption, including decreases in urinary calcium and urinary markers of bone collagen degradation [0m[1;31m([0m[31msuch as deoxypyridinoline and cross-linked N-telopeptides of type I collagen[0m[1;31m)[0m[31m. [0m
[31mThese biochemical changes tended to return toward baseline values as early as [0m[1;31m3[0m[31m weeks following the discontinuation of therapy with alendronate and did not differ from placebo after [0m[1;31m7[0m[31m months. [0m
[31mLong-term treatment of osteoporosis with alendronate sodium [0m[1;31m10[0m[31m mg/day [0m[1;31m([0m[31mfor up to five years[0m[1;31m)[0m[31m reduced urinary excretion of markers of bone resorption, deoxypyridinoline and cross-linked N-telopeptides [0m
[31mof type l collagen, by approximately [0m[1;31m50[0m[31m% and [0m[1;31m70[0m[31m%, respectively, to reach levels similar to those seen in healthy premenopausal women. ALENDRONATE SODIUM: pharmacodynamics: Similar decreases were seen [0m
[31min patients in osteoporosis prevention studies who received alendronate sodium [0m[1;31m5[0m[31m mg/day. The decrease in the rate of bone resorption indicated by these markers was evident as early as [0m[1;31m1[0m[31m month and at [0m[1;31m3[0m
[31mto [0m[1;31m6[0m[31m months reached a plateau that was maintained for the entire duration of treatment with alendronate sodium. In osteoporosis treatment studies alendronate sodium [0m[1;31m10[0m[31m mg/day decreased the markers of [0m
[31mbone formation, osteocalcin and bone specific alkaline phosphatase by approximately [0m[1;31m50[0m[31m%, and total serum alkaline phosphatase by approximately [0m[1;31m25[0m[31m to [0m[1;31m30[0m[31m% to reach a plateau after [0m[1;31m6[0m[31m to [0m[1;31m12[0m[31m months. In [0m
[31mosteoporosis prevention studies alendronate sodium [0m[1;31m5[0m[31m mg/day decreased osteocalcin and total serum alkaline phosphatase by approximately [0m[1;31m40[0m[31m% and [0m[1;31m15[0m[31m%, respectively.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE SODIUM label[0m


[31mCONTENT: ALENDRONATE SODIUM: clinical_pharmacology: [0m[1;31m12[0m[31m CLINICAL PHARMACOLOGY [0m[1;31m12.1[0m[31m Mechanism of Action Animal studies have indicated the following mode of action. At the cellular level, alendronate [0m
[31mshows preferential localization to sites of bone resorption, specifically under osteoclasts. The osteoclasts adhere normally to the bone surface but lack the ruffled border that is indicative of [0m
[31mactive resorption. Alendronate does not interfere with osteoclast recruitment or attachment, but it does inhibit osteoclast activity. Studies in mice on the localization of radioactive [0m[1;31m[[0m[31m [0m[1;31m3[0m[31m [0m
[31mH[0m[1;31m][0m[31malendronate in bone showed about [0m[1;31m10[0m[31m-fold higher uptake on osteoclast surfaces than on osteoblast surfaces. Bones examined [0m[1;31m6[0m[31m and [0m[1;31m49[0m[31m days after [0m[1;31m[[0m[31m [0m[1;31m3[0m[31m H[0m[1;31m][0m[31malendronate administration in rats and mice, [0m
[31mrespectively, showed that normal bone was formed on top of the alendronate, which was incorporated inside the matrix. ALENDRONATE SODIUM: clinical_pharmacology: While incorporated in bone matrix, [0m
[31malendronate is not pharmacologically active. Thus, alendronate must be continuously administered to suppress osteoclasts on newly formed resorption surfaces. Histomorphometry in baboons and rats [0m
[31mshowed that alendronate treatment reduces bone turnover [0m[1;31m([0m[31mi.e., the number of sites at which bone is remodeled[0m[1;31m)[0m[31m. In addition, bone formation exceeds bone resorption at these remodeling sites, leading [0m
[31mto progressive gains in bone mass. [0m[1;31m12.2[0m[31m Pharmacodynamics Alendronate is a bisphosphonate that binds to bone hydroxyapatite and specifically inhibits the activity of osteoclasts, the bone-resorbing [0m
[31mcells. Alendronate reduces bone resorption with no direct effect on bone formation, although the latter process is ultimately reduced because bone resorption and formation are coupled during bone [0m
[31mturnover. ALENDRONATE SODIUM: clinical_pharmacology: Osteoporosis in Postmenopausal Women Osteoporosis is characterized by low bone mass that leads to an increased risk of fracture. The diagnosis can [0m
[31mbe confirmed by the finding of low bone mass, evidence of fracture on x-ray, a history of osteoporotic fracture, or height loss or kyphosis, indicative of vertebral [0m[1;31m([0m[31mspinal[0m[1;31m)[0m[31m fracture. Osteoporosis [0m
[31moccurs in both males and females but is most common among women following the menopause, when bone turnover increases and the rate of bone resorption exceeds that of bone formation. These changes [0m
[31mresult in progressive bone loss and lead to osteoporosis in a significant proportion of women over age [0m[1;31m50[0m[31m. Fractures, usually of the spine, hip, and wrist, are the common consequences. From age [0m[1;31m50[0m[31m to [0m
[31mage [0m[1;31m90[0m[31m, the risk of hip fracture in white women increases [0m[1;31m50[0m[31m-fold and the risk of vertebral fracture [0m[1;31m15[0m[31m- to [0m[1;31m30[0m[31m-fold. ALENDRONATE SODIUM: clinical_pharmacology: It is estimated that approximately [0m[1;31m40[0m[31m% [0m
[31mof [0m[1;31m50[0m[31m-year-old women will sustain one or more osteoporosis-related fractures of the spine, hip, or wrist during their remaining lifetimes. Hip fractures, in particular, are associated with substantial[0m
[31mmorbidity, disability, and mortality. Daily oral doses of alendronate sodium [0m[1;31m([0m[1;31m5[0m[31m, [0m[1;31m20[0m[31m, and [0m[1;31m40[0m[31m mg for six weeks[0m[1;31m)[0m[31m in postmenopausal women produced biochemical changes indicative of dose-dependent [0m
[31minhibition of bone resorption, including decreases in urinary calcium and urinary markers of bone collagen degradation [0m[1;31m([0m[31msuch as deoxypyridinoline and cross-linked N-telopeptides of type I collagen[0m[1;31m)[0m[31m. [0m
[31mThese biochemical changes tended to return toward baseline values as early as [0m[1;31m3[0m[31m weeks following the discontinuation of therapy with alendronate and did not differ from placebo after [0m[1;31m7[0m[31m months. [0m
[31mALENDRONATE SODIUM: clinical_pharmacology: Long-term treatment of osteoporosis with alendronate sodium [0m[1;31m10[0m[31m mg/day [0m[1;31m([0m[31mfor up to five years[0m[1;31m)[0m[31m reduced urinary excretion of markers of bone resorption, [0m
[31mdeoxypyridinoline and cross-linked N-telopeptides of type l collagen, by approximately [0m[1;31m50[0m[31m% and [0m[1;31m70[0m[31m%, respectively, to reach levels similar to those seen in healthy premenopausal women. Similar [0m
[31mdecreases were seen in patients in osteoporosis prevention studies who received alendronate sodium [0m[1;31m5[0m[31m mg/day. The decrease in the rate of bone resorption indicated by these markers was evident as early[0m
[31mas [0m[1;31m1[0m[31m month and at [0m[1;31m3[0m[31m to [0m[1;31m6[0m[31m months reached a plateau that was maintained for the entire duration of treatment with alendronate sodium.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE SODIUM label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: Alendronate Sodium can cause upper gastrointestinal adverse reactions, which may include esophagitis, esophageal ulcers, and esophageal erosions, occasionally with bleeding. These reactions [0m
[32mcan be severe and may require hospitalization. However, there is no specific mention of a general increased risk of bleeding outside of these gastrointestinal events.[0m

[32mSOURCE: ALENDRONATE SODIUM label[0m
[32mEXTRACT_START_END: [0m[32m...[0m[32mEsophageal adverse experiences, such as esophagitis, esophageal ulcers and esophageal erosions, occasionally with bleeding[0m[32m...[0m
*[1m([0morchestrator-bleeding-ALENDRONATE SODIUM[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: Alendronate Sodium can cause upper gastrointestinal adverse [0m
[34mreactions, which may include esophagitis, esophageal ulcers, and esophageal erosions, occasionally with bleeding. These reactions can be severe and may require hospitalization. However, there is no [0m
[34mspecific mention of a general increased risk of bleeding outside of these gastrointestinal events.[0m

[34mSOURCE: ALENDRONATE SODIUM label[0m
[34mEXTRACT_START_END: [0m[34m...[0m[34mEsophageal adverse experiences, such as esophagitis, esophageal ulcers and esophageal erosions, occasionally with bleeding[0m[34m...[0m
 [1m([0morchestrator-bleeding-ALENDRONATE SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-ALENDRONATE SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-bleeding-ALENDRONATE SODIUM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does ALENDRONATE SODIUM increase or decrease the risk of bleeding?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether ALENDRONATE SODIUM increases the risk of bleeding."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that Alendronate Sodium can cause upper gastrointestinal adverse reactions, which may include esophagitis, esophageal ulcers, and esophageal erosions, occasionally with [0m
[32mbleeding. These reactions can be severe and may require hospitalization. However, there is no specific mention of a general increased risk of bleeding outside of these gastrointestinal events."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"Alendronate Sodium may increase the risk of bleeding, but this is specifically in the context of upper gastrointestinal adverse reactions such as esophagitis, esophageal ulcers, and [0m
[32mesophageal erosions. There is no specific mention of a general increased risk of bleeding outside of these gastrointestinal events according to the FDA label data."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-bleeding-ALENDRONATE SODIUM[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-bleeding-ALENDRONATE SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-bleeding-ALENDRONATE SODIUM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-bleeding-ALENDRONATE SODIUM[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does ALENDRONATE SODIUM increase or decrease the risk of bleeding?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether ALENDRONATE SODIUM increases the risk of bleeding."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that Alendronate Sodium can cause upper gastrointestinal adverse reactions, which may include esophagitis, esophageal ulcers, and esophageal erosions, occasionally with [0m
[34mbleeding. These reactions can be severe and may require hospitalization. However, there is no specific mention of a general increased risk of bleeding outside of these gastrointestinal events."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"Alendronate Sodium may increase the risk of bleeding, but this is specifically in the context of upper gastrointestinal adverse reactions such as esophagitis, esophageal ulcers, and [0m
[34mesophageal erosions. There is no specific mention of a general increased risk of bleeding outside of these gastrointestinal events according to the FDA label data."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does ALENDRONATE SODIUM increase or decrease the risk of bleeding?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether ALENDRONATE SODIUM increases the risk of bleeding.[0m
[1;31m2[0m[31m. FDAHandler responded that Alendronate Sodium can cause upper gastrointestinal adverse reactions, which may include esophagitis, esophageal ulcers, and esophageal erosions, occasionally with [0m
[31mbleeding. These reactions can be severe and may require hospitalization. However, there is no specific mention of a general increased risk of bleeding outside of these gastrointestinal events.[0m
[31m        -----[0m
[31m        Final answer: Alendronate Sodium may increase the risk of bleeding, but this is specifically in the context of upper gastrointestinal adverse reactions such as esophagitis, esophageal ulcers, [0m
[31mand esophageal erosions. There is no specific mention of a general increased risk of bleeding outside of these gastrointestinal events according to the FDA label data.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-bleeding-ALENDRONATE SODIUM[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-bleeding-ALENDRONATE SODIUM[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-bleeding-ALENDRONATE SODIUM[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-bleeding-ALENDRONATE SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-bleeding-ALENDRONATE SODIUM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mAlendronate Sodium may increase the risk of bleeding, but this is specifically in the context of upper gastrointestinal adverse reactions such as esophagitis, esophageal ulcers, and esophageal [0m
[32merosions. There is no specific mention of a general increased risk of bleeding outside of these gastrointestinal events according to the FDA label data.[0m
